Global Zoladex Market Growth (Status and Outlook) 2023-2029

Global Zoladex Market Growth (Status and Outlook) 2023-2029

Product Code:460467

Published Date: Feb 08,2023

Pages: 60

Region: Global

Category: Pharma & Healthcare

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US

Zoladex is a medication which is used to suppress production of the sex hormones (testosterone and estrogen), particularly in the treatment of breast and prostate cancer. It is an injectable gonadotropin releasing hormone agonist (GnRH agonist).

Zoladex (goserelin acetate) Implant is a man-made form of a hormone used in men to treat symptoms of prostate cancer, and in women to treat breast cancer or endometriosis. Zoladex is also used in women to prepare the lining of the uterus for endometrial ablation (a surgery to correct abnormal uterine bleeding).

LPI (LP Information)' newest research report, the “Zoladex Industry Forecast” looks at past sales and reviews total world Zoladex sales in 2022, providing a comprehensive analysis by region and market sector of projected Zoladex sales for 2023 through 2029. With Zoladex sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Zoladex industry.

This Insight Report provides a comprehensive analysis of the global Zoladex landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Zoladex portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Zoladex market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Zoladex and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Zoladex.

The global Zoladex market size is projected to grow from US$ 982.2 million in 2022 to US$ 1158.4 million in 2029; it is expected to grow at a CAGR of 2.4% from 2023 to 2029.

The global Zoladex market includes several companies. However, AstraZeneca is in a dominant position in the production market, accounting for over 85% of the market share.

Asia-Pacific is the largest consumption region, with a consumption market share of nearly 60%. Following Asia-Pacific, Europe is the second largest consumption area with a consumption market share of about 15%.

The classification of Zoladex includes 1M Zoladex and 3M Zoladex. The proportion of 1M Zoladex is over 60%.

Moreover, Zoladex is widely used for Prostate Cancer, Breast Cancer, Endometriosis, Fibroids, etc. The most proportion of Zoladex is used for Prostate Cancer, and the proportion is about 45%.

This report presents a comprehensive overview, market shares, and growth opportunities of Zoladex market by product type, application, key players and key regions and countries.

Market Segmentation:
Segmentation by type
    1M Zoladex
    3M Zoladex

Segmentation by application
    Prostate Cancer
    Breast Cancer
    Endometriosis
    Fibroids
    Others

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    AstraZeneca
    TerSera